Since the response to cetuximab in CRC is impaired by KRAS/BRAF mutations [4–6], these do not affect their response to OxPt [7, 8] since the latter is incorporated through the hCTR1 transporter activated by Cu chelation. Here, KRAS is linked to colorectal carcinoma.